Compare

Treace Medical Concepts/$TMCI

1D1W1M3M6MYTD1Y5YMAX

About Treace Medical Concepts

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
Ticker
$TMCI
Sector
Health
Primary listing
NASDAQ
Employees
450
Headquarters
Ponte Vedra, United States
Website
www.treace.com

TMCI Metrics

BasicAdvanced
$329M
-
-$0.86
-
-

What the Analysts think about TMCI

Analyst ratings (Buy, Hold, Sell) for Treace Medical Concepts stock.
Analyst projections of the future price of Treace Medical Concepts stock.

Bulls say / Bears say

Case volumes grew at a high-single-digit rate in the second quarter, while 40% of Lapiplasty surgeons had adopted at least one of the newer bunion systems. That wider portfolio could help Treace win more procedures and bring new surgeons into its core offering. (Treace Medical Concepts)
Cost control is improving: second-quarter operating expenses fell 8%, and the company cut year-to-date cash usage by 57%. Treace also narrowed its expected 2026 adjusted EBITDA loss, signalling progress towards better operating leverage. (Treace Medical Concepts)
Five-year Lapiplasty study results showed low reported recurrence and sustained improvements in patient-reported outcomes. Durable results may strengthen the procedure’s appeal to surgeons and help distinguish Treace’s offering. (Treace Medical Concepts)
Revenue fell 4% in the second quarter despite faster case growth, as sales shifted towards lower-priced minimally invasive products. Full-year guidance still implies revenue could fall by as much as 4%, and gross margin also declined year on year. (Treace Medical Concepts)
Treace faces intensifying competition and a shift in surgeon and patient preference towards minimally invasive procedures. Its latest filing also warns that lower reimbursement at ambulatory surgery centres and the stronger contracting power of larger device companies could weigh on access and pricing. (StockTitan)
The company remains loss-making, with a second-quarter net loss of $15.9 million and an expected adjusted EBITDA loss of $3 million to $5 million for 2026. Its $45.6 million in cash and marketable securities leaves limited room for error if losses and cash use persist. (Treace Medical Concepts)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.

TMCI Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

TMCI Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

TMCI News

AllArticlesVideos

What Treace Medical Concepts (TMCI) Said on Its Q3 Earnings Call

MarketBeat6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.